Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
AuthorsBarrett-Lee, P J
Dixon, J M
Plummer, C J
Verrill, Mark W
AffiliationBreast Unit, Velindre Cancer Centre, Cardiff, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractAnthracyclines are considered to be among the most active agents for the treatment of breast cancer. However, their use is limited by cumulative, dose-related cardiotoxicity. Such cardiotoxicity results in a permanent loss of cardiac myocytes and a progressive reduction in cardiac function following each subsequent dose of anthracycline. Initially, damage to the heart is subclinical; however, increasingly impaired cardiac function can result in cardiovascular symptoms, with serious cardiac injury resulting in chronic heart failure. Since the early detection and treatment of cardiotoxicity can reduce its clinical effects, it is important that oncologists are aware of these adverse effects and manage them appropriately. This review examines the risk factors for anthracycline-associated cardiotoxicity and offers recommendations on strategies to reduce the cardiotoxicity of anthracyclines in the management of patients with advanced breast cancer.
CitationExpert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. 2009, 20 (5):816-27 Ann. Oncol.
JournalAnnals of Oncology
- Anthracycline cardiotoxicity after breast cancer treatment.
- Authors: Hershman DL, Shao T
- Issue date: 2009 Mar
- Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
- Authors: Chung WB, Youn HJ
- Issue date: 2016 Jul
- Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
- Authors: Henriksen PA
- Issue date: 2018 Jun
- Monitoring of anthracycline-induced cardiotoxicity.
- Authors: Jannazzo A, Hoffman J, Lutz M
- Issue date: 2008 Jan
- [Cardiotoxicity of anthracyclines].
- Authors: Costache II, Petriş A
- Issue date: 2011 Oct-Dec